The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 in adults at high risk for progressing to severe COVID-19 disease, including hospitalization and death.
- Risk for progression includes age > 60, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
- Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
- In February 2023, the FDA updated the EUA by removing the need for a positive COVID-19 viral test to prescribe the medication
Molnupiravir is NOT authorized for:
There's more to see -- the rest of this topic is available only to subscribers.